RXRX Q2 2025 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+32.6% YoY

Gross Profit

-$1M-5.5% margin

Operating Income

-$176M-922.5% margin

Net Income

-$172M-899.8% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+29.6%

Cash Flow

Operating Cash Flow

-$76M

Free Cash Flow

-$80M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$383M

Stockholders' Equity

$919M

Cash & Equivalents

$528M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$14M	+32.6%
Gross Profit	-$1M	$5M	-120.3%
Operating Income	-$176M	-$101M	-75.3%
Net Income	-$172M	-$98M	-76.2%

Revenue Segments

License and Service

$19M99%

Grant

$120,0001%

Geographic Segments

UNITED STATES

$12M100%